April 27, 2022
After a busy first quarter attending virtual meetings, the Partnerships team is pleased to announce our in-person attendance at a series of hematology congresses in the coming months.
Our Senior Partnerships Manager Geoff Jones will be in Paris for the 8th World Congress on Controversies in Multiple Myeloma (COMy) on May 12–15. If you are attending the event and would like to know more about the Multiple Myeloma Hub—an SES and European School of Haematology (ESH) partnered platform—please email Geoff Jones directly.
Partnerships Director Ken Zangina will be in Copenhagen for the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress on June 1–3 to grow the footprint for our new immunology platform, the Lupus Hub (lupushub.com). Please email Ken Zangina directly should you wish to meet to discuss supporting this platform.
Members of the Partnerships team will be available to meet in person on both sides of the Atlantic for the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) congresses on June 3–7 and June 9–12, respectively. We look forward to connecting with our industry partners and contacts and providing some fantastic updates from our hematology platforms, particularly with regard to engagement statistics from Q1, 2022. Please contact the partnerships team on should you wish to meet at either of these events.
We are delighted to welcome Sanofi as the third founding supporter of the Rare Anaemias International Network (RAIN). RAIN is a global community-based ecosystem comprising patient advocacy associations and individuals supporting rare anemias. With the first of two annual member meetings due to take place in the coming months, it is exciting to have a significant industry stakeholder in the treatment of Cold Agglutinin Disease (CAD) involved with the initiative. Growing the industry support for RAIN is critical to achieving its mission of improving the health and quality of life of people with rare anemias.
We are delighted to confirm that AbbVie will be continuing their support of the Multiple Myeloma Hub. As a Silver supporter, AbbVie’s sponsorship of this platform along with our existing industry partners is highly valued and enables the SES team to deliver significant innovations on the platform, such as the recent Google Translate feature, which helps to expand the hub’s global reach.
We are pleased to announce Daiichi Sankyo as confirmed supporters of the Lymphoma Hub in 2022. The addition of this organization at Contributor level highlights the strong support that this platform continues to enjoy from industry partners. Content from the Lymphoma Hub reached 68,546 users in 2021, and we hope to build upon this footprint in 2022 with the development of exciting new features on the platforms. Meanwhile, we are focused on delivering quality, diverse content that is of value to the healthcare community in lymphoma and CLL.
Bespoke Educational Opportunities
We are seeking grants from our existing and new industry partners to ensure that the following newly created bespoke educational initiatives have credible representation across the scope of therapies.
“Towards personalized therapy in relapsed multiple myeloma”
This digital symposium will help users describe novel therapeutic targets in multiple myeloma and explain the mechanisms of action for new agents in the disease space. Users will also be able to
state the rationale for selecting treatments in relapsed/refractory disease based on disease- and patient-related factors. The symposium will be designed in collaboration with the experienced and world-renowned Multiple Myeloma Hub Steering Committee to ensure relevance and accuracy in addition to attracting a big audience.
“Beyond JAK inhibition: novel agents for the treatment of advanced myelofibrosis”
This clinical trials club is a live webinar series where one of our steering committee members will be joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trials clubs effectively support healthcare professionals in understanding what the latest news means for clinical practice. This clinical trials club offers the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in myeloproliferative neoplasms.”
“How to select and sequence treatments for steroid-refractory GvHD”
This interactive case study educational project will offer users the potential to transition from simple knowledge gains to changes in patient care outcomes in the management of this challenging patient group. Learners will be presented with a patient case, identified challenge, or specific decision, along with supporting data. The learner will be guided/coached by a leading expert based on their treatment decision and provided with the correct answer. After engaging with this content, we hope users will be able to explain the role of new agents in the graft-versus-host disease therapeutic landscape, including optimal patient selection and sequencing.
Please contact the Partnerships team on if you would like to learn more about supporting these educational initiatives.
Looking to receive the latest news, project updates, and new offerings?